key: cord-0846240-lifpzjna authors: Bao, Jianfeng; Xie, Zhijun; Liu, Shourong; Huang, Lin; Sun, Jing; Tang, Yujun; Chen, Haiping; Qi, Jianjiang; Guo, Jianchun; Miao, Liangbin; Li, Zhaoyi; Yang, Hui; Zhang, Yi; Li, Zhiyu; Xu, Yuan; Lin, Shengyou; Xun, Yunhao; Zhang, Li; Bao, Jie; Cai, Zhaobin; Huang, Jinsong; Wen, Chengping title: Treatment Effects of Integrated TCM and Western Medicine Treatment Scheme on COVID-19: A Single-armed Clinical Trial date: 2021-11-14 journal: Clinical Complementary Medicine and Pharmacology DOI: 10.1016/j.ccmp.2021.100009 sha: a06e85759fa32bb93b2be5d6b79d286f78860314 doc_id: 846240 cord_uid: lifpzjna Backgroud : The outbreak of COVID-19 has brought unprecedented perils to human health and raised public health concerns in more than two hundred countries. Safe and effective treatment scheme is needed urgently. Objective : To evaluate the effects of integrated TCM and western medicine treatment scheme on COVID-19. Methods : A single-armed clinical trial was carried out in Hangzhou Xixi Hospital, an affiliated hospital with Zhejiang Chinese Medical University. 102 confirmed cases were screened out from 725 suspected cases and 93 of them were treated with integrated TCM and western medicine treatment scheme. Results : 83 cases were cured, 5 cases deteriorated, and 5 cases withdrew from the study. No deaths were reported. The mean relief time of fever, cough, diarrhea, and fatigue were (4.78±4.61) days, (7.22±4.99) days, (5.28± 3.39) days, and (5.28± 3.39) days, respectively. It took (14.84±5.50) days for SARS-CoV-2 by nucleic acid amplification-based testing to turn negative. Multivariable cox regression analysis revealed that age, BMI, PISCT, BPC, AST, CK, BS, and UPRO were independent risk factors for COVID-19 treatment. Conclusion : Our study suggested that integrated TCM and western medicine treatment scheme was effective for COVID-19. Research showed that the combination of western medicine and TCM had better performance on reducing fatality, alleviating symptoms, and curtailing hospitalization. In this present study, a single-arm, open-label trial of COVID-19 therapy was carried out to evaluate both the efficacy and safety on the combined application of western medicine and TCM [4] [5] [6] [7] [8] [9] [10] . The single-armed, open-label study was conducted in Hangzhou Xixi Hospital, an affiliated hospital with Zhejiang Chinese Medical University. This study was registered at the Chinese Clinical Trial Registry (Register NO. ChiCTR2000029578) and was approved by the Medical Ethics Committee of Hangzhou Xixi Hospital (Approval NO.2020-KLS-15). By March 2nd, 2020, a total of 725 suspected patients of COVID-19, either exposed to the virus or with a history of fever were considered for the study. 105 among such suspects, who"s respiratory or blood specimens were tested SARS-COV-2-positive consecutively twice by the nucleic acid amplification-based tests were diagnosed as confirmed cases. Among them, 12 cases declined to participate, therefore 93 cases were enrolled in the subsequent clinical trial. During the treatment and follow-up, 5 cases withdrew, and the symptoms of other 5 patients were exacerbated and transformed into critical pneumonia. Finally, 83 participants completed the full treatment scheme and the follow-up. All the patients were provided with informed consent and signed agreement. Patients who met the criteria of the Diagnosis and Treatment Protocol for COVID -19 were included and assigned according to their symptoms as classified by the Protocol to mild, moderate, and severe groups, respectively [11] . Mild group patients were characterized by mild respiratory symptoms with no imaging manifestations of pneumonia; the moderate group patients were characterized by clinical symptoms that included fever, respiratory symptoms, and imaging manifestations of pneumonia. The severe group patients should meet at least one of the following conditions: 1) Respiratory distress (respiratory rate is ≥30 times/minute) 2) Oxygen saturation under the resting state is ≤93%. 3) Arterial blood oxygen partial pressure / oxygen concentration is ≤300mmHg. The exclusion criteria were 1) patients in critical stage; 2) patients with other serious organ diseases or mental diseases. Standard of cure in this study was defined as follows: patients' body temperature returned to normal for >3d; respiratory symptoms were significantly alleviated; obvious absorption of inflammation from lung imaging was observed; two consecutive negative results of respiratory pathogen nucleic acid tests were obtained. Patients were suggested to take bed rest and receive other support including strengthening treatments, balanced intake of water and electrolytes, and close monitoring of oxygen saturation. All patients were treated with alpha-interferon nebulization (5 million units each time for adults, added to 2ml of sterilized water for injection twice daily) or lopinavir (200mg, two capsules each time, twice a day for 5 days). Inappropriate use of antibacterial drugs was avoided, in particular the combined use of broad-spectrum antibacterial drugs. The prescription for patients in mild group included 9g of Pogostemon cablin Continuous variables were expressed as mean±SD or median (IQR) and compared with the Paired t-test or one-way ANOVA; categorical variables were expressed as number (%) and compared by χ² test or Fisher"s exact test or the Matching Rank Sum test. The comparison of grade variables was analyzed by Ridit analysis. The cure rate was analyzed with survival analysis-life tables, and factors affecting disease improvement were analyzed by multivariable cox regression model. Edition) issued by the National Health Commission of People"s Republic of China on February 4th, 2020 (http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm), all the 105 participants shared the main symptoms, such as fever, cough, expectoration, diarrhea, and fatigue, were classified into the mild, moderate, and severe stages, respectively ( Figure 1A ). Table 1 and Table 2 , the levels of C reactive protein (CRP), lactate dehydrogenase (LDH), and urine protein (UPRO) were all raised, and the CRP levels in severe patients were significantly higher than those in the mild-type patients (P < 0.05), and Globulin (GLB) and Albumin (ALB) levels between moderate-type and severe-type patients were significantly different (P < 0.05). UPRO was found to be elevated in 41 cases (44.09%). Furthermore, according to Ridit analysis, we found that the pulmonary infiltration signs by computerized tomography (PISCT) were significantly different between mild, moderate, and severe COVID-19 participants (P < 0.05) ( Table 2) . The participants with mild COVID-19 were all cured without exacerbation. As for the moderate patients, symptoms of two patients deteriorated into critical COVID-19, and five were transferred to other local hospitals for personal reasons and dropped out. Three cases in the severe group were cured, and symptoms of other three patients were exacerbated. The total exacerbation rate was 5.38%. There was no death reported (Table 3 ). The median cure time was 14.67 days, and the cure rate was 41.8% on day 14, 80.2% on day 21, and 98.1% on day 28, respectively ( Figure 1B ). As shown in Figure 2 , all clinical symptoms were improved after treatment. The mean relief times of fever, cough, diarrhea and fatigue of the total COVID-19 participators were (4.78±4.61) days, (7.22±4.99) days, (5.28± 3.39) days and (5.28± 3.39) days, respectively (Table 4) , and the relief time of mild COVID-19 participators was shorter than other COVID-19 participates. It took an average of (14.84±5.50) days for the SARS-Cov-2-positive cases to turn negative, as indicated by the nucleic acid amplification-based testing. Specifically, the recovery time in mild, moderate, and severe groups participants were (14.44±8.25) days, (14.86±5.11) days, and (15.67±5.11) days, respectively ( Figure 3A ). Table 5 and Figure 3B , all the participants' UPRO and PISCT were significantly improved (P < 0.01). As analyzed by the Matching Rank Sum test, the level of CRP, Aspartate Aminotransferase (AST), LDH, Blood Sugar (BS) of all the participants improved after treatment (P < 0.05). Finally, we analyzed the prognostic factor for COVID-19 outcomes by using Cox regression analysis. As shown in Table 6 , age, body mass index (BMI), PISCT, blood platelet count (BPC), AST, CK, BS, UPRO were included into the model equation and found that CK, BS, UPRO (+), and UPRO (2+) were the significant prognostic factors for COVID-19 outcomes (P < 0.05). Fifteen participators" Alanine Aminotransferase (ALT) increased during the treatment. However, they all returned to normal after taking diammonium glycyrrhizinate capsules for liver protection treatment (Table 7) . The outbreak of COVID-19 has brought unprecedented perils to human health and raised public health concerns in more than two hundred countries. In a study with western medicine intervention, 26% of COVID-19 patients received ICU care, with a fatality rate of 4.3%. After one month of treatment, 47 (34.1%) were discharged from the hospital, and the median hospitalization time of the 47 discharged patients was 10 (7.0 to 14.0) days [12] . A clinical retrospective study of 34 cases COVID-19 treated with integrated TCM and western medicine showed that the clinical cure rate and exacerbation rate in the integrated TCM and Western Medicine group were significantly better than those in the western treatment group (94.1% vs 61.1% and 5.9% vs 33.3%, respectively) [13] . This paper here reported a prospective study involving 105 COVID-19-positive patients, result of which revealed both efficacy and safety of the treatment scheme applied. Symptoms of COVID-19 fitted well with the "cold-dampness epidemic disease (han-shi-yi)" in TCM theory. The formula "Chu-shi-tang" was used to protect mild- The median cure time was 14.67 days, and the cure rate was 41.8% on day 14, 80.2% on day 21, and 98.1% on day 28, respectively, and the total exacerbation rate was 5.38%. Fortunately, the fatality rate was 0%. Moreover, the 10 withdrawal cases were all recovered. This study's cure rate, exacerbation rate, and fatality rate were better than the data reported by CCDC (98.10% vs 64.86%, 5.38% vs 7.39%, and 0% vs 3.74%). In addition, the total cure rate and exacerbation rate in this study were also better than those in the western medicine group reported in the clinical retrospective study (98.10% vs 61.1%, 5.38% vs 33.3%) [13] . The trial showed the efficacy and safety of western medicine combined with TCM in treating different stage COVID-19 patients. It has been reported that SARS-CoV-2 utilized angiotensin-converting enzyme 2 as a cell receptor [14] . During this process, spike protein (S protein) on the surface of the [15] [16] [17] [18] . Based on the network pharmacology and molecular docking method, Zong et al. [19] found that quercetin, kaempferol, formononetin, and baicalein could bind to 2019-nCoV 3CL hydrolase and inhibit virus invasion. Moreover, Scutellaria baicalensis could inhibit the inflammatory reaction and reduce the damage of the human immune system [20, 21] . During the study, liver damage and abnormal gastrointestinal activities occurred in some patients, which might be related to antiviral drugs [22, 23] . Nevertheless, these side-effects were slight and controllable. In conclusion, results showed that the integrated TCM and western medicine treatment approach was effective and safe. Compared with conventional Western medicine treatment, integrated TCM and Western medicine treatment has shown to be more promising and worthy of further clinical reference and application. Our team plans for more in-depth research on the mechanism of TCM treatment of COVID-19 from the aspects of antiviral, regulation of microecology, and immunity. The study was approved by the ethical committee of Hangzhou Xixi Hospital affiliated to Zhejiang Chinese Medical University (2020-KLS-15). Additional data are available on reasonable request. This Research was Supported by Zhejiang Provincial Natural Science Foundation of China "Emergency Prevention and Treatment of COVID-19", Under Grated NO. LEZ20H190001 and COVID-19 prevention and control special scientific research project of Hangzhou Science and Technology Bureau, China. All authors declare no competing interests. CRedit authorship contribution statement CW, ZX, JB, ZC, and JH had the idea for and designed the study, had full access to all data in the study, and took responsibility for the data's integrity and the accuracy of the data analysis. JB, SL, HC, JG, LM, ZL, YT, YZ, and ZL collected the clinical data. ZX, LH, YZ, JS, and CW contributed to the writing of the report. ZX and HY contributed to the statistical analysis. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version. Note. Compared with mild NCP, ** P < 0.01；Compared with moderate NCP, △ P < 0. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Clinical investigation of traditional Chinese medicine in treatment of 71 patients with severe acute respiratory syndrome Clinical observation on the treatment of 16 cases of SARS with traditional Chinese medicine Clinical summary of treating 37 cases of SARS in emergency room of First Hospital Affiliated to Guangzhou University of Traditional Chinese Medicine Clinical Characteristics and Integrative Chinese and Western Medicine Treatment of 42 Patients of Severe Acute Respiratory Syndrome(SARS) The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenzarelated symptoms, and improve quality of life: a prospective cohort study Using herbal medicine as a means of prevention experience during the SARS crisis Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Clinical study on 34 novel coronavirus pneumoniae treated with integrated traditional Chinese and Western Medicine Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Forsythiae Fructus: A Review on its Phytochemistry, Quality Control, Pharmacology and Pharmacokinetics Antiviral herbs--present and future Immunomodulatory and anti-SARS activities of Houttuynia cordata Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study Exploring the active compounds of Da-Yuan-Yin in treatment of novel coronavirus (2019-nCoV) pneumonia based on network pharmacology and molecular docking method Anti-inflammatory Mechanism of Antipyretic and Detoxifying Traditional Chinese Medicine Research of Effective Components of Scutellariae Radix on Action Targets in Inflammation Pathway Disrupted ER-to-Golgi Trafficking Underlies Anti-HIV Drugs and Alcohol-Induced Cellular Stress and Hepatic Injury Dolutegravir versus ritonavirboosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. The Lancet Infectious diseases Note. Compared with mild NCP, * P < 0.05；Compared with moderate NCP, △ P < 0.05. BMI: Body Mass Index, WBC: White Blood Cell, LYMPH: Percentage of lymphocytes, CRP: c-reactive protein, ALT: alanine aminotransferase, AST: aspartate aminotransferase, GLB: Globulin, ALB：Albumin, Src: serum creatinine, BUN: blood urea nitrogen, LDH: lactate dehydrogenase, CK: creatine kinase, BS: blood sugar We acknowledge all health-care workers involved in the diagnosing and treating of patients in Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University; we thank the Zhejiang Health Commission for coordinating data collection for patients with COVID-19 infection. Chenping Wen, 0000-0001-9254-6235. Nil.